Effects of Pioglitazone on High-Fat-Diet–Induced Ventricular Remodeling and Dysfunction in Rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 2, 2012, Pages 223-228

  Tian, ya Qiang ^a,b   Li, Shou She ^a   Su, Xu Dong ^a   Zhang, Guang Zhen ^a   Zhao, Jia Jun ^b   li, Guang Wei ^c   Wang, Lexin ^d  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

angiotensin II; cardiac function; high fat diet; pioglitazone; ventricular hypertrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FATTY ACID; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE REMODELING; LIPID DIET; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; DIET, HIGH-FAT; ECHOCARDIOGRAPHY; FATTY ACIDS, NONESTERIFIED; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIUM; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES; TRIGLYCERIDES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84867147394     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411423022     Document Type: Article

References (29)

1. Grandi AM Maresca AM Giudici E, et al. Metabolic syndrome and morpho-functional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens. 2006; 19(2):199-205.
2. Naour N Rouault C Fellahi S, et al. Cardiovasular changes in obese subjects on very low calorie diet. Int J Obes. 1989; 13(suppl 2):95-99.
3. Després JP Lemieux I Bergeron J, et al. Abdominal obesity and the metabolic syndrome contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008; 28(6):1039-1049.
4. Bays HE González-Campoy JM Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovase Ther. 2008; 6(3):343-368.
5. Nissen SE Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-2471.
6. Russell JC Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol. 2006; 15(6):318-330.
7. Kraegen EW James DE Bennett SP Chisholm DJ. In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol. 1983; 245(1):E1-E7.
8. Folch J Lees M Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957; 226(1):497-509.
9. Grundy SM Hansen B Smith SC Jr Cleeman JI Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004; 109(4):551-556.
10. Kenchaiah S Evans JC Levy D, et al. Obesity and the risk of the heart failure. N Engl J Med. 2002; 347(5):305-313.
11. Di Stante B Galandauer I Aronow WS, et al. Prevalence of left ventricular diastolic dysfunction in obese persons with and without diabetes mellitus. Am J Cardiol. 2005; 95(12):1527-1528.
12. Hinrichs S Heger J Schreckenberg R, et al. Controlling cardiomyocyte length: the role of renin and PPAR-(gamma). Cardiovasc Res. 2011; 89(2):344-352.
13. Shah P Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf. 2010; 9(2):347-354.
14. Dormandy JA Charbonnel B Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-1289.
15. Baranowski M Blachnio-Zabielska A Zabielski P Gorski J. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Arch Biochem Biophys. 2008; 477(1):86-91.
16. Nakamura T Yamamoto E Kataoka K, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension. 2008; 51(2):296-301.
17. Zib I Jacob AN Lingvay I, et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med. 2007; 55(5):230-236.
18. Yagyu H Chen G Yokoyama M, et al. Lipoprotein lipase(LPL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest. 2003; 111(3):419-427.
19. Christoffersen C Bollano E Lindegaard ML, et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003; 144(8):3483-3490.
20. Unger RH. Mini review. Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144(12):5159-5165.
21. Coort SL Hasselbaink DM Koonen DP, et al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myoctytes from obese Zucker rats. Diabetes. 2004; 53(7):1655-1663.
22. Zhou YT Grayburn P Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci. 2000; 97(4):1874-1879.
23. Dewald O Sharma S Adrogue J, et al. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation. 2005; 112(3):407-415.
24. Finck BN Lehman JJ Leone TC, et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2001; 109(1):121-130.
25. Paradis P Dali-Youcef N Paradis FW Thibault G Nemer M. Overexpression of angiotensinII type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci. 2000; 97(2):931-936.
26. Huang W Xie C Zhou H Yang T Sun M. Association of the angiotensin2 converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail. 2004; 6(1):23-27.
27. Abraham MR Olson LJ Joyner MJ Turner ST Beck KC Johnson BD. Angiotensin2 converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation. 2002; 106(14):1794-1799.
28. du Toit EF Nabben M Lochner A. A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/reperfusion injury. Basic Res Cardiol. 2005; 100(4):346-354.
29. Grossman LD Parlan G Bailey AL Yee G Yu M Chan JY. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin Therap. 2009; 31(1):74-88.